OBI Pharma, Inc. (4174.TWO)
TWD 51.2
(-8.24%)
TWD 51.2
(-8.24%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 41.54 Million TWD | 781.96% |
| 2022 | 4.71 Million TWD | -74.9% |
| 2021 | 18.77 Million TWD | -86.68% |
| 2020 | 140.88 Million TWD | 16056.65% |
| 2019 | 872 Thousand TWD | -93.46% |
| 2018 | 13.33 Million TWD | 3447.61% |
| 2017 | 376 Thousand TWD | -99.59% |
| 2016 | 92.42 Million TWD | 0.0% |
| 2015 | - TWD | 0.0% |
| 2014 | - TWD | 0.0% |
| 2013 | - TWD | 0.0% |
| 2012 | - TWD | 0.0% |
| 2011 | - TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 19.01 Million TWD | 108.17% |
| 2024 Q1 | 9.13 Million TWD | -50.4% |
| 2024 Q3 | 22.97 Million TWD | 20.84% |
| 2023 Q3 | 11.47 Million TWD | 16.3% |
| 2023 Q4 | 18.41 Million TWD | 60.5% |
| 2023 FY | 41.54 Million TWD | 781.96% |
| 2023 Q1 | 1.78 Million TWD | 252.27% |
| 2023 Q2 | 9.86 Million TWD | 452.52% |
| 2022 FY | 4.71 Million TWD | -74.9% |
| 2022 Q3 | 1.07 Million TWD | -42.45% |
| 2022 Q1 | 1.26 Million TWD | -49.76% |
| 2022 Q2 | 1.86 Million TWD | 48.14% |
| 2022 Q4 | 507 Thousand TWD | -52.84% |
| 2021 Q4 | 2.51 Million TWD | -9.91% |
| 2021 FY | 18.77 Million TWD | -86.68% |
| 2021 Q2 | 9.01 Million TWD | 102.15% |
| 2021 Q3 | 2.78 Million TWD | -69.1% |
| 2021 Q1 | 4.46 Million TWD | -94.42% |
| 2020 Q1 | 279 Thousand TWD | -8.52% |
| 2020 Q3 | 554 Thousand TWD | -99.08% |
| 2020 Q2 | 60.18 Million TWD | 21472.4% |
| 2020 FY | 140.88 Million TWD | 16056.65% |
| 2020 Q4 | 79.86 Million TWD | 14316.25% |
| 2019 Q2 | 136 Thousand TWD | -36.45% |
| 2019 FY | 872 Thousand TWD | -93.46% |
| 2019 Q1 | 214 Thousand TWD | -22.74% |
| 2019 Q3 | 217 Thousand TWD | 59.56% |
| 2019 Q4 | 305 Thousand TWD | 40.55% |
| 2018 Q3 | 315 Thousand TWD | -20.25% |
| 2018 Q1 | 12.35 Million TWD | 123420.0% |
| 2018 FY | 13.33 Million TWD | 3447.61% |
| 2018 Q4 | 277 Thousand TWD | -12.06% |
| 2018 Q2 | 395 Thousand TWD | -96.8% |
| 2017 FY | 376 Thousand TWD | -99.59% |
| 2017 Q4 | 10 Thousand TWD | 0.0% |
| 2017 Q3 | - TWD | -100.0% |
| 2017 Q2 | 366 Thousand TWD | 0.0% |
| 2017 Q1 | - TWD | -100.0% |
| 2016 FY | 92.42 Million TWD | 0.0% |
| 2016 Q1 | - TWD | 0.0% |
| 2016 Q4 | 36 Thousand TWD | 0.0% |
| 2016 Q2 | 92.38 Million TWD | 0.0% |
| 2016 Q3 | - TWD | -100.0% |
| 2015 Q2 | - TWD | 0.0% |
| 2015 FY | - TWD | 0.0% |
| 2015 Q4 | - TWD | 0.0% |
| 2015 Q3 | - TWD | 0.0% |
| 2015 Q1 | - TWD | 0.0% |
| 2014 Q3 | - TWD | 0.0% |
| 2014 Q2 | - TWD | 0.0% |
| 2014 Q1 | - TWD | 0.0% |
| 2014 FY | - TWD | 0.0% |
| 2014 Q4 | - TWD | 0.0% |
| 2013 Q1 | - TWD | 0.0% |
| 2013 Q2 | - TWD | 0.0% |
| 2013 FY | - TWD | 0.0% |
| 2013 Q3 | - TWD | 0.0% |
| 2013 Q4 | - TWD | 0.0% |
| 2012 Q4 | - TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2012 FY | - TWD | 0.0% |
| 2011 FY | - TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| SYN-TECH Chem. & Pharm. Co., Ltd. | 1.11 Billion TWD | 96.273% |
| Level Biotechnology Inc. | 660.61 Million TWD | 93.711% |
| Sagittarius Life Science Corp | 440.46 Million TWD | 90.567% |
| NeoCore Technology Co., Ltd. | 64.72 Million TWD | 35.811% |
| TaiMed Biologics Inc. | 491.77 Million TWD | 91.551% |
| GlycoNex Incorporation | 2.54 Million TWD | -1534.5% |
| VBI | 55.85 Million TWD | 25.61% |
| GeneReach Biotechnology Corp. | 225.46 Million TWD | 81.571% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 315.98 Million TWD | 86.851% |
| Visgeneer Inc. | 147.99 Million TWD | 71.925% |
| Mycenax Biotech Inc. | 652.62 Million TWD | 93.634% |
| Sunmax Biotechnology Co., Ltd. | 1.68 Billion TWD | 97.54% |
| G&E Herbal Biotechnology Co., Ltd. | 181.44 Million TWD | 77.101% |
| Medigen Vaccine Biologics Corporation | 389.62 Million TWD | 89.336% |
| TaiwanJ Pharmaceuticals Co., Ltd. | 22.74 Million TWD | -82.697% |
| Enimmune corporation | 43.49 Million TWD | 4.472% |
| TaiRx, Inc. | 5.08 Million TWD | -717.572% |
| CHO Pharma, Inc. | - TWD | -Infinity% |
| EirGenix Inc. | 1.02 Billion TWD | 95.937% |
| BioLASCO Taiwan Co., Ltd. | 264.72 Million TWD | 84.305% |
| Sunny Pharmtech Inc. | 428.82 Million TWD | 90.311% |
| Lin BioScience, Inc. | - TWD | -Infinity% |
| BioGend Therapeutics Co., Ltd. | 109.9 Million TWD | 62.197% |
| Feng Chi Biotech Corp. | 180.57 Million TWD | 76.991% |
| Bio Preventive Medicine Corp. | 1.2 Million TWD | -3339.487% |
| Lukas Biomedical Inc. | 231.83 Million TWD | 82.078% |
| RBC Bioscience Corporation | 172.46 Million TWD | 75.909% |
| BiOptic Inc. | 228.26 Million TWD | 81.798% |
| BRIM Biotechnology, Inc. | 90 Thousand TWD | -46065.556% |
| Shine-On BioMedical Co.,Ltd. | 9.52 Million TWD | -336.256% |
| Great Novel Therapeutics Biotech & Medicals | 4.85 Million TWD | -756.68% |
| Syngen Biotech Co.,Ltd. | 1.83 Billion TWD | 97.738% |
| Anti-Microbial Savior BioteQ Co., Ltd | 728 Thousand TWD | -5607.28% |
| SynCore Biotechnology Co.,Ltd | 20.19 Million TWD | -105.729% |
| Genomics BioSci & Tech. Co.,Ltd. | 396.14 Million TWD | 89.512% |
| Neith Corporation | 39.9 Million TWD | -4.125% |
| Advagene Biopharma Co., Ltd. | - TWD | -Infinity% |
| NaviFUS Corp. | 22.48 Million TWD | -84.818% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 141.17 Million TWD | 70.569% |
| Sinew Pharma Inc. | - TWD | -Infinity% |
| Andros Pharmaceuticals Co.,Ltd | 805 Thousand TWD | -5061.366% |
| Greenyn Biotechnology Co., Ltd | 800.51 Million TWD | 94.81% |
| Lumosa Therapeutics Co., Ltd. | 56.91 Million TWD | 26.999% |
| AP Biosciences Inc | 32.25 Million TWD | -28.822% |
| Medigen Biotechnology Corp. | 1.15 Billion TWD | 96.411% |
| 3D Global Biotech Inc. | 20.63 Million TWD | -101.372% |
| Pharmosa Biopharm Inc. | 314.5 Million TWD | 86.789% |
| Intech Biopharm Corporation | 25.84 Million TWD | -60.75% |
| Oneness Biotech Co., Ltd. | 86.78 Million TWD | 52.123% |
| Eusol Biotech Co.,Ltd. | - TWD | -Infinity% |
| TWi Biotechnology, Inc. | - TWD | -Infinity% |
| Ever Supreme Bio Technology Co., Ltd | 758.39 Million TWD | 94.521% |
| TCI GENE Inc. | 333.85 Million TWD | 87.555% |
| MegaPro Biomedical Co., Ltd | 18 Thousand TWD | -230727.778% |
| Senhwa Biosciences, Inc. | 1 Million TWD | -4054.9% |
| Taiwan Bio Therapeutics Co., Ltd | 85.47 Million TWD | 51.388% |
| NatureWise Biotech & Medicals Corporation | 160.14 Million TWD | 74.055% |
| PharmaEngine, Inc. | 767.66 Million TWD | 94.588% |
| Savior Lifetec Corporation | 1.05 Billion TWD | 96.044% |
| TaiGen Biopharmaceuticals Holdings Limited | 123.13 Million TWD | 66.257% |
| Meribank Biotech Co., Ltd | 234.34 Million TWD | 82.27% |
| Acepodia, Inc. | 16.59 Million TWD | -150.401% |
| Caliway Biopharmaceuticals Co., Ltd. | 38.93 Million TWD | -6.722% |